This article is more than 5 years old. Information may no longer be current.
Heidelberg adds two new OCT models to Spectralis line
Click Here to Manage Email Alerts
VISTA, Calif. — Two new spectral domain optical coherence tomography models with laser autofluorescence technology have been added to Heidelberg Engineering's Spectralis ophthalmic imaging device family, a press release from the company announced.
The new devices increase the offering of the BluePeak laser autofluorescence technology to five of the Spectralis models, including the "company's more economical spectral domain OCT devices," the release said.
According to Karl Csaky, MD, PhD, BluePeak laser autofluorescence measures the metabolic activity of the retinal pigment epithelium, a component of retinal function.
"Recent results from the Geographic Atrophy Progression study clearly demonstrate the need to use autofluorescence to track the progression of geographic atrophy for dry AMD patients," he said in the release. "This has attracted the interest of the pharmaceutical companies; at least 10 new therapies for dry AMD are now under clinical investigation. The combination of BluePeak and OCT will enable clinicians to potentially take advantage of these emerging therapeutics in the same way that ranibizumab and OCT changed the management of wet AMD."